Bristol-Myers Squibb Company (BMY)

63.33
NYSE : Health Care
Prev Close 63.33
Day Low/High 0.00 / 0.00
52 Wk Low/High 46.01 / 63.74
Avg Volume 6.16M
Exchange NYSE
Shares Outstanding 1.64B
Market Cap 104.12B
EPS 2.70
P/E Ratio 23.17
Div & Yield 1.56 (2.50%)

Latest News

Japan Ministry Of Health, Labor And Welfare Approves Opdivo (nivolumab) For The Treatment Of Patients With Unresectable Advanced Or Recurrent Gastric Cancer Which Has Progressed After Chemotherapy

Japan Ministry Of Health, Labor And Welfare Approves Opdivo (nivolumab) For The Treatment Of Patients With Unresectable Advanced Or Recurrent Gastric Cancer Which Has Progressed After Chemotherapy

Bristol-Myers Squibb Company (NYSE:BMY) today announced that the Japanese Ministry of Health, Labor and Welfare (MHLW) has approved Opdivo (nivolumab) for the treatment of unresectable advanced or recurrent gastric...

Bristol-Myers Squibb To Take Part In Leerink Partners Rare Disease & Immuno-Oncology Roundtable Conference

Bristol-Myers Squibb To Take Part In Leerink Partners Rare Disease & Immuno-Oncology Roundtable Conference

Bristol-Myers Squibb Company (NYSE:BMY) will take part in Leerink Partners Rare Disease & Immuno-Oncology Roundtable Conference on Thursday, September 28, 2017, in New York.

New Global Report Finds Majority Of People At High Risk Of Stroke Not Being Screened For Common Risk Factors

New Global Report Finds Majority Of People At High Risk Of Stroke Not Being Screened For Common Risk Factors

New research released today by The Economist Intelligence Unit (EIU), a division of The Economist and a leader in global business intelligence, revealed that on average, more than 75 percent of people aged 65 and older...

Bristol-Myers Squibb Stock Still a Beast?

Bristol-Myers Squibb Stock Still a Beast?

The drug-maker's stock just keeps going higher. What is the next move?

Time to Adjust as Bristol-Myers Squibb Continues Its Climb

Time to Adjust as Bristol-Myers Squibb Continues Its Climb

It just keeps going higher.

There Are Good Opportunities in Stock Picking

There Are Good Opportunities in Stock Picking

The indices may need a rest, but stock-pickers have an edge.

Halozyme Jumps on Immuno-Oncology Deal with Bristol-Myers

Halozyme Jumps on Immuno-Oncology Deal with Bristol-Myers

Pharma giant aims to develop cancer drug delivery technology. Halozyme shares are up more than 16% in pre-market trading.

Bristol-Myers Squibb And Halozyme Enter Global Collaboration And License Agreement For ENHANZE Technology

Bristol-Myers Squibb And Halozyme Enter Global Collaboration And License Agreement For ENHANZE Technology

Bristol-Myers Squibb Company (NYSE:BMY) and Halozyme Therapeutics, Inc.

Bristol-Myers Squibb Announces Dividend

Bristol-Myers Squibb Announces Dividend

The Board of Directors of Bristol-Myers Squibb Company (NYSE:BMY) today declared a quarterly dividend of thirty-nine cents ($0.

Bristol-Myers Squibb Names Karen Vousden, Ph.D. To Board Of Directors

Bristol-Myers Squibb Names Karen Vousden, Ph.D. To Board Of Directors

Bristol-Myers Squibb Company (NYSE:BMY) today announced that its Board of Directors has elected Karen Vousden, Ph.

Achillion Shares Are Plunging on Termination of Hepatitis C Pact

Achillion Shares Are Plunging on Termination of Hepatitis C Pact

The New Haven, Conn.-based firm on Sept. 9 received a termination notice regarding its license and collaboration pact with Johnson & Johnson's Janssen Pharmaceuticals Inc. on hepatitis C.

Opdivo (nivolumab) Demonstrates Superior Recurrence-Free Survival Versus Yervoy (ipilimumab) For Patients With Resected High-Risk Melanoma In Phase 3 CheckMate -238 Study

Opdivo (nivolumab) Demonstrates Superior Recurrence-Free Survival Versus Yervoy (ipilimumab) For Patients With Resected High-Risk Melanoma In Phase 3 CheckMate -238 Study

Bristol-Myers Squibb Company (NYSE: BMY) announced today that treatment with Opdivo (nivolumab) 3 mg/kg resulted in a significant improvement in recurrence-free survival (RFS) compared to Yervoy (ipilimumab) 10...

Opdivo Plus Yervoy Combination Demonstrated Superior Overall Survival And Showed Durable Responses In Patients With Previously Untreated Advanced Or Metastatic Renal Cell Carcinoma In Phase 3 CheckMate -214 Trial

Opdivo Plus Yervoy Combination Demonstrated Superior Overall Survival And Showed Durable Responses In Patients With Previously Untreated Advanced Or Metastatic Renal Cell Carcinoma In Phase 3 CheckMate -214 Trial

Bristol-Myers Squibb Company (NYSE:BMY) announced today results from the Phase 3 CheckMate -214 trial evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) versus sunitinib in patients with previously untreated advanced...

Two Pivotal Opdivo (nivolumab) Trials Show Three-Year Survival Benefit In Patients With Previously Treated Advanced Non-Small Cell Lung Cancer

Two Pivotal Opdivo (nivolumab) Trials Show Three-Year Survival Benefit In Patients With Previously Treated Advanced Non-Small Cell Lung Cancer

Bristol-Myers Squibb Company (NYSE:BMY) today announced three-year overall survival (OS) data from CheckMate -017 and CheckMate -057, two pivotal Phase 3 randomized studies evaluating Opdivo versus docetaxel in...

Someone's Betting Big on the VIX

And they believe it's going down.

Bristol-Myers Squibb Completes Previously Announced Acquisition Of IFM Therapeutics

Bristol-Myers Squibb Completes Previously Announced Acquisition Of IFM Therapeutics

Bristol-Myers Squibb Company (NYSE:BMY) today announced that it has completed the previously announced planned acquisition of IFM Therapeutics.

CheckMate -214 Study Evaluating Opdivo In Combination With Yervoy Stopped Early For Demonstrating Overall Survival Benefit In Patients With Previously Untreated Advanced Or Metastatic Renal Cell Carcinoma

CheckMate -214 Study Evaluating Opdivo In Combination With Yervoy Stopped Early For Demonstrating Overall Survival Benefit In Patients With Previously Untreated Advanced Or Metastatic Renal Cell Carcinoma

Bristol-Myers Squibb Company (NYSE:BMY) announced today that a Phase 3 study evaluating Opdivo plus Yervoy in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC) met its co-primary...

Bristol-Myers Squibb To Announce Results For Third Quarter 2017 On October 26

Bristol-Myers Squibb To Announce Results For Third Quarter 2017 On October 26

Bristol-Myers Squibb Company (NYSE:BMY) will announce results for the third quarter of 2017 on Thursday, October 26, 2017.

(Graphic: Business Wire)

(Graphic: Business Wire)

The first of seven teams of Bristol-Myers Squibb (NYSE:BMY) employees mounted their bikes in Cannon Beach, OR, today to kick off the 2017 Coast 2 Coast 4 Cancer Ride.

Walmart Is One of 63 Companies Contributing Massively to Aid Harvey Relief

Walmart Is One of 63 Companies Contributing Massively to Aid Harvey Relief

Corporations have contributed at least $141.3 million to aid Hurricane Harvey relief efforts, as of Friday.

Bristol-Myers Squibb To Take Part In Morgan Stanley Global Health Care Conference

Bristol-Myers Squibb To Take Part In Morgan Stanley Global Health Care Conference

Bristol-Myers Squibb Company (NYSE:BMY) will take part in the Morgan Stanley 2017 Global Health Care Conference on Monday, September 11, 2017, in New York.

Sneaky Rally; Wells Fargo Needs Outside Help -- Jim Cramer's Top Thoughts

Sneaky Rally; Wells Fargo Needs Outside Help -- Jim Cramer's Top Thoughts

Cramer reflects on good news stirring a sneaky rally, and how Wells Fargo needs outside leadership.

Juno, bluebird In Focus as Targets Following Gilead-Kite Aquisition

Juno, bluebird In Focus as Targets Following Gilead-Kite Aquisition

More Immunotherapy Buyouts Likely After Kite Sale

Bristol-Myers Squibb, Pfizer, Abbott Are on the Move: Buy These Target Prices

Bristol-Myers Squibb, Pfizer, Abbott Are on the Move: Buy These Target Prices

Check out these three big movers today.

Bristol-Myers Squibb Is Primed for an Upside Breakout

Bristol-Myers Squibb Is Primed for an Upside Breakout

Prices have test $60 several times, but this looks like the real deal.

Bristol-Myers Squibb Data At ESMO 2017 Demonstrate Company's Innovative Research Approach To Treating Cancer From All Angles

Bristol-Myers Squibb Data At ESMO 2017 Demonstrate Company's Innovative Research Approach To Treating Cancer From All Angles

Bristol-Myers Squibb Company (NYSE:BMY) today announced more than 60 presentations, including seven late-breaking abstracts, from its Oncology portfolio will be featured at the European Society for Medical Oncology...

Cramer: Good News Stirs a Sneaky Rally

Cramer: Good News Stirs a Sneaky Rally

We are also seeing some stocks that are just too strong for their own good.

Taking Bristol-Myers Trade off the Table

Taking Bristol-Myers Trade off the Table

Our strategy has captured some time decay on the short call and a lift on the long call side.

TheStreet Quant Rating: B (Buy)